Dactinomycin 0.5mg Injection

Dactinomycin 0.5mg is a cytotoxic chemotherapy used in Wilms tumour, rhabdomyosarcoma, Ewing sarcoma and gestational trophoblastic disease. It is often included in a planned combination of chemotherapy, surgery or radiotherapy.
The prepared dose is administered into a vein with careful observation of the intravenous line. Treatment days are coordinated with the cancer regimen and any radiotherapy.
Dactinomycin binds to DNA and prevents production of RNA. This blocks protein production and growth in susceptible tumour cells.
Nausea, vomiting, mouth inflammation, hair loss and low blood counts can occur. Serious liver injury and severe local tissue damage after leakage are important risks.
Previous or planned radiotherapy matters because dactinomycin can intensify tissue reactions. Blood counts and liver tests guide further courses.
Supports tumour shrinkage and disease control in established multi-treatment cancer programmes.
Yes. Radiation recall can cause inflammation in an earlier radiation field even after radiotherapy has finished.
These can be signs of liver-related fluid retention or hepatic sinusoidal obstruction and need prompt assessment.
No. Although it belongs to the antitumour antibiotic class, it is used as chemotherapy rather than as a routine infection treatment.
Tell the nurse immediately. Early recognition of leakage helps limit tissue injury.
Antitumour antibiotic: a chemotherapy class rather than a routine infection medicine. Radiation recall: inflammation in a previously irradiated area. Sinusoidal obstruction: blockage affecting small vessels in the liver.; AR: Dactinomycin 0.5mg حقن; FR: Dactinomycin 0.5mg injection; PT: Dactinomycin 0.5mg injeção; ES: Dactinomycin 0.5mg inyección; RU: Dactinomycin 0.5mg инъекция; ID: Dactinomycin 0.5mg suntikan; VI: Dactinomycin 0.5mg thuốc tiêm; MS: Dactinomycin 0.5mg suntikan; TL: Dactinomycin 0.5mg iniksyon; ZH-SG: Dactinomycin 0.5mg 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Dactinomycin 0.5mg Injection under Oncology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Dactinomycin 0.5mg Injection